<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626465</url>
  </required_header>
  <id_info>
    <org_study_id>2021-01971</org_study_id>
    <nct_id>NCT05626465</nct_id>
  </id_info>
  <brief_title>Biomarker-s of Abusive Head Trauma by Proteomics</brief_title>
  <official_title>Identification of Novel Biomarker-s of Abusive Head Trauma on Serum by Proteomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to highlight biomarker-s of Abusive Head Trauma by proteomics&#xD;
      analyses on the serum of child victims of abuse.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2023</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Highlight novel biomarker-s of AHT</measure>
    <time_frame>Hospital admission to discharge (up to 3 days)</time_frame>
    <description>Proteomic analyses will be made on serum of infant victim of AHT. Results will be compare with control groups (traumatic brain injury, cranioplasty, malaise).</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Abuse, Child</condition>
  <condition>Protein Disorder, Blood</condition>
  <arm_group>
    <arm_group_label>Abusive Head Trauma (AHT)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Accidental traumatic brain injury</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cranioplasty</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant malaise without AHT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Proteomic analyses on serum</description>
    <arm_group_label>Abusive Head Trauma (AHT)</arm_group_label>
    <arm_group_label>Accidental traumatic brain injury</arm_group_label>
    <arm_group_label>Cranioplasty</arm_group_label>
    <arm_group_label>Infant malaise without AHT</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infant between 0 to 2 y.o&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age : 0-2 y.o&#xD;
&#xD;
          -  Medical consultation for malaise, seizure (without fever), loss of consciousness,&#xD;
             traumatic bain injury, or cranioplasty&#xD;
&#xD;
          -  Blood test during medical care&#xD;
&#xD;
          -  Accepted informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refused informed consent&#xD;
&#xD;
          -  For control groups : medical history of child abuse&#xD;
&#xD;
          -  For AHT group : rare metabolic disease (Menkes, etc..)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Fracasso, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Wiskott, MD</last_name>
    <phone>0041797737424</phone>
    <email>kim.wiskott@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ginhoux Thiphanie</name>
      <address>
        <city>Lyon</city>
        <state>Rh√¥ne</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thiphanie Ginhoux</last_name>
      <phone>+33(0)4 27 85 77 23</phone>
      <email>tiphanie.ginhoux01@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wiskott Kim</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Kim Wiskott</last_name>
      <email>kim.wiskott@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Sergio Manzano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 15, 2022</study_first_submitted>
  <study_first_submitted_qc>November 15, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>January 11, 2023</last_update_submitted>
  <last_update_submitted_qc>January 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Kim Wiskott</investigator_full_name>
    <investigator_title>Dre Kim Wiskott</investigator_title>
  </responsible_party>
  <keyword>abusive head trauma</keyword>
  <keyword>proteomic</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Blood Protein Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

